Association of galectin-3 expression with melanoma progression and prognosis

European Journal of Cancer

Volumn 48, Issue 6, 2012, Pages 865-874

  Brown, Ewan R ^a   Doig, Tamasin ^a   Anderson, Niall ^b   Brenn, Thomas ^a   Doherty, Val ^c   Xu, Yan ^b   Bartlett, John M S ^b   Smyth, John F ^a   Melton, David W ^b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c NHS LOTHIAN   (United Kingdom)

Author keywords

BRAF; Galectin 3; Melanoma; Prognosis

Indexed keywords

B RAF KINASE; GALECTIN 3;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CYTOPLASM; DYSPLASTIC NEVUS; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MUTATIONAL ANALYSIS; NEVUS; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADULT; AGED; ANALYSIS OF VARIANCE; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FEMALE; GALECTIN 3; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MICROARRAY ANALYSIS; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS B-RAF; RISK FACTORS; SCOTLAND; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84859101615     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.09.003     Document Type: Article

References (38)

1. H. Tsao, M.B. Atkins, and A.J. Sober Management of cutaneous melanoma N Engl J Med 351 2004 998 1012
2. C.M. Balch, J. Gershenwald, and S. Soong Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 2009 6199 6206
3. K. Flaherty, I. Puzanov, and K. Kim Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819
4. W.H. Clark Jr., and D.E. Elder A study of tumour progression: the precursor lesions of superficial spreading and nodular melanoma Hum Pathol 15 1984 1147 1165 (Pubitemid 15128121)
5. M.Y. Hsu, M. Meier, and M. Herlyn Melanoma development and progression: a conspiracy between tumor and host Differentiation 70 2002 522 536 (Pubitemid 36194317)
6. S. Nakahara, N. Oka, and A. Raz On the role of galectin-3 in cancer apoptosis Apoptosis 10 2005 267 275 (Pubitemid 40603482)
7. V.G. Prieto, A.A. Mourad-Zeidan, and V. Melinikova Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma Clin Cancer Res 15 2006 6709 6715 (Pubitemid 44876839)
8. P. Nangia-Makker, S. Nakahara, and V. Hogan Galectin-3 in apoptosis, a novel therapeutic target J Bioenerg Biomembr 39 2007 79 84 (Pubitemid 46877176)
9. T. Kirkegaard, J. Edwards, and S. Tovey Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 48 2006 787 794 (Pubitemid 43800937)
10. M.T. Landi, J. Bauer, and R.M. Pfeiffer MC1R germline variants confer risk for BRAF-mutant melanoma Science 313 2006 521 522 (Pubitemid 44148456)
11. N. Hayashida, H. Namba, and A. Kumagai A rapid and simple detection method for the BRAF(T1796A) mutation in fine-needle aspirated thyroid carcinoma cells Thyroid 14 2004 910 915 (Pubitemid 39612909)
12. D.L. Dai, M. Martinka, and G. Li Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases J Clin Oncol 23 2005 1473 1482
13. A.M. Karst, D.L. Dai, M. Martinka, and G. Li PUMA expression is significantly reduced in human cutaneous melanomas Oncogene 24 2005 1111 1116 (Pubitemid 40313889)
14. J. Rangel, M. Nosrati, and L. Shaikh Osteopontin as a molecular prognostic marker for melanoma Cancer 112 2008 144 150
15. J. Rangel, S. Torabian, and L. Shaikh Prognostic significance of nuclear receptor coactivator-3 over expression in primary cutaneous melanoma J Clin Oncol 2 2006 4565 4569 (Pubitemid 46630952)
16. M.D. Pacifico, R. Grover, and P.I. Richman Nm23 as a prognostic marker in primary cutaneous melanoma: evaluation using tissue microarray in a patient group with long-term follow-up Melanoma Res 15 2005 435 440 (Pubitemid 41558954)
17. V. Castronovo, F.A. Van Den Brule, and P. Jackers Decreased expression of galectin-3 is associated with progression of human breast cancer J Pathol 179 1996 46 48
18. X. Sanjuan, P.L. Fernandez, and A. Castells Differential expression of galectin-3 and galectin-1 in colorectal cancer progression Gastroenterology 13 1997 1906 1915 (Pubitemid 27512149)
19. F.A. Van den Brule, D. Waltregny, and F.T. Liu Alterations of the cytoplasmic/nuclear expression patterns of galectin-3 correlates with prostate carcinoma progression Int J Cancer 89 2000 361 367 (Pubitemid 30620290)
20. G. Choufani, S. Nagy, and H. Saussez The levels of expression of galectin-1, galectin-3 and Thomas-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers Cancer 86 1999 2353 2363 (Pubitemid 30010378)
21. M. Nakamura, H. Inufusa, and T. Adachi Involvement of galectin-3 expression in colorectal cancer progression and metastasis Int J Cancer 15 1999 143 148
22. Y. Matsuda, Y. Yamagiwa, and K. Fukushima Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma Hepatol Res 38 2008 1098 1111
23. K. Erido, S. Kohnoe, and E. Tsujita Galectin-3 expression is a potent prognostic marker in colorectal cancer Anticancer Res 25 2005 3117 3121
24. Y. Honjo, H. Inohara, and S. Akahani Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma Clin Cancer Res 6 2000 4635 4640 (Pubitemid 32110398)
25. K. Okada, T. Shimura, and T. Suehiro Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer Anticancer Res 36 2006 1369 1376
26. A.S. Merseburger, M.W. Kramer, and J. Hennenlotter Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival World J Urol 26 2008 637 642
27. M. Junking, C. Wongkham, and B. Sripa Decreased expression of galectin-3 is associated with metastatic potential of liver fluke-associated cholangiocarcinoma Eur J Cancer 44 2008 619 626
28. T. Shimamura, M. Sakamoto, and Y. Ino Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas Clin Cancer Res 8 2002 2570 2575 (Pubitemid 34856341)
29. A.G. Abdou, M.A. Hammam, and S. El Farargy Diagnostic and prognostic role of galectin 3 expression in cutaneous melanoma Am J Dermatopathol 32 8 2010 809 815
30. P. Vereecken, C. Debray, and M. Petein Expression of galectin-3 in primary and metastatic melanoma: immunohistochemical studies on human lesions and nude mice xenograft tumours Arch Dermatol Res 296 2005 353 358 (Pubitemid 40310807)
31. M. Buljan, M. Situm, and D. Tomas Prognostic value of galectin-3 in primary cutaneous melanoma J Eur Acad Dermatol Venereol 22 2010 1 8
32. L.A. Akslen, S. Angelini, and O. Straume Braf mutation and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival J Invest Dermatol 125 2005 312 317 (Pubitemid 41648165)
33. J.A. Curtin, J. Fridlyand, and T. Kageshita Distinct sets of genetic alterations in melanoma N Engl J Med 353 2005 2135 2147 (Pubitemid 41653105)
34. W. Liu, J.W. Kelly, and M. Trivett Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma J Invest Dermatol 127 2007 900 905 (Pubitemid 46434654)
35. A. Viros, J. Fridlyand, and J. Bauer Improving melanoma classification by integrating genetic and morphologic features PLoS Med 5 2008 e120
36. J. Bauer, P. Büttner, and R. Murali BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site Pigm Cell Melanoma Res 24 2011 345 351
37. N.L. Perillo, M.E. Marcus, and L.G. Baum Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death J Mol Med 76 1998 402 412 (Pubitemid 28218642)
38. J. Ochieng, B. Green, and S. Evans Modulation of the biological functions of galectin-3 by matrix metalloproteinases Biochim Biophys Acta 1379 1998 97 106 (Pubitemid 28045559)